ZLAB Zai Lab Limited

Asian equities traded in the US as American depositary receipts were heading lower in Thursday tradi

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.

Zai Lab stock presents a challenging valuation picture for investors, with a share price that has risen in the shorter term but sits against a five year record of heavy value loss and only a mixed read from broader valuation checks. The share price has fallen 80.9% over the past five years, which points to a significant destruction of shareholder value over a full market cycle. Future revenue growth from its biopharmaceutical portfolio can support the current valuation, while ongoing...

Asian equities traded in the US as American depositary receipts were edging lower Friday morning, de

Asian equities traded in the US as American depositary receipts were tracking higher Wednesday morni

Asian equities traded in the US as American depositary receipts started the week lower Monday mornin

Asian equities traded in the US as American depositary receipts were rising sharply Friday morning,

Asian equities traded in the US as American depositary receipts were tracking higher Tuesday morning

Zai Lab Limited American Depositary Shares (NASDAQ:ZLAB) and argenx SE (NASDAQ:ARGX) announced positive topline results on August 17 from their Phase 3 ALKIVIA study evaluating VYVGART Hytrulo in adults with autoimmune myositis. In the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population, patients treated with efgartigimod achieved a statistically significant, 15.4-point greater improvement in […]

Asian equities traded in the US as American depositary receipts were tracking modestly higher Wednes

Asian equities traded in the US as American depositary receipts were marginally higher Thursday morn

Zoci advances toward global registrational trials as net product revenue rises 11%.

Asian equities traded in the US as American depositary receipts were edging slightly lower Tuesday m

Zai Lab Limited reported second-quarter 2026 results showing revenue of US$106.31 million versus US$109.98 million a year earlier, with net loss widening to US$50.83 million from US$40.73 million and basic loss per share increasing to US$0.50 from US$0.40. Over the first half of 2026, revenue slipped to US$205.92 million while net loss deepened to US$101.84 million, suggesting higher costs or investment needs are weighing more heavily on the income statement than a year ago. We will now...

Zai Lab (ZLAB) stock is in focus after the company reported second quarter 2026 results, including revenue of US$106.31 million and a net loss of US$50.83 million, with wider losses than a year earlier. See our latest analysis for Zai Lab. The earnings release seems to have shifted sentiment toward Zai Lab in the short term, with an 11.69% 1 day share price return and a 27.64% 7 day share price return. However, the 1 year total shareholder return is still down 33.30%, which points to short...

Zai Lab (NASDAQ:ZLAB) said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a global biopharmaceutical business. Founder, Chairperson and CEO Samantha Du said the company is advanc

Asian equities traded in the US as American depositary receipts were tracking higher Friday morning,

Zai Lab Ltd (ZLAB) advances its DLL3 ADC pipeline with three registrational programs expected by year-end, while navigating a strategic shift toward global expansion over near-term profitability.

Asian equities traded in the US as American depositary receipts were tracking higher Thursday mornin

The headline numbers for Zai Lab Limited (ZLAB) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.